Literature DB >> 11391624

Deletion mapping of chromosome 16q24 in hepatocellular carcinoma in Taiwan and mutational analysis of the 17-beta-HSD gene localized to the region.

Y W Lin1, I N Lee, C H Chen, G T Huang, H S Lee, P H Lee, F J Lu, J C Sheu.   

Abstract

Human chromosome band 16q24 commonly undergoes loss of heterozygosity (LOH) in human hepatocellular carcinoma (HCC). To further localize the region of deletion on 16q24 and to evaluate the genetic role of 17-beta-HSD, which is near 16q24, in HCC, we examined the pattern of loss of heterozygosity in 88 HCC patients. DNAs from 88 pairs of HCCs and corresponding non-tumor parts were prepared. Loss of heterozygosity on chromosomes 16q24 was investigated by 11 sets of microsatellite markers. Mutation analysis of type II 17-beta-HSD was performed by automatic sequencing. LOH on 16q24 for at least 1 locus was found in 43 of the 88 tumor DNAs (49%). Three non-overlapping regions of frequent LOH were defined in these 43 tumors with partial deletions. The first region was between D16S516 loci and D16S507, encompassed by a 1-cM region, defined by the D16S504. The second region was defined by the 17HSDB2 locus between D16S505 and D16S422, encompassed approximately by a 1-cM region. The third region was between D16S520 and D16S413, defined by D16S3048, encompassed approximately by a 4-cM region. Homozygous deletions of any exons in 17HSDB2 gene were identified in 7 of 27 cases (26%). Automated sequencing analysis of 17HSDB2 failed to demonstrate mutations in any of these specimens. Our data suggest that the 17HSDB2 locus is a frequent target of deletion in HCC but the inactivation of 17HSDB2 may not involve sequence mutations. Furthermore, the presence of the other 2 frequent LOH regions suggest that the putative tumor suppressor genes at these locations might be involved in the development of HCC. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391624     DOI: 10.1002/ijc.1287

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  SCF-FBXO31 E3 ligase targets DNA replication factor Cdt1 for proteolysis in the G2 phase of cell cycle to prevent re-replication.

Authors:  Pegah Johansson; Jessie Jeffery; Fares Al-Ejeh; Renèe B Schulz; David F Callen; Raman Kumar; Kum Kum Khanna
Journal:  J Biol Chem       Date:  2014-05-14       Impact factor: 5.157

2.  Degradation of FBXO31 by APC/C is regulated by AKT- and ATM-mediated phosphorylation.

Authors:  Srinadh Choppara; Sunil K Malonia; Ganga Sankaran; Michael R Green; Manas Kumar Santra
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-17       Impact factor: 11.205

3.  CRL Ubiquitin Ligases and DNA Damage Response.

Authors:  Ju-Mei Li; Jianping Jin
Journal:  Front Oncol       Date:  2012-04-09       Impact factor: 6.244

4.  MicroRNA-210 interacts with FBXO31 to regulate cancer proliferation cell cycle and migration in human breast cancer.

Authors:  Dayue Liu; Haoming Xia; Fang Wang; Cui Chen; Jianting Long
Journal:  Onco Targets Ther       Date:  2016-08-23       Impact factor: 4.147

Review 5.  Ubiquitination in melanoma pathogenesis and treatment.

Authors:  Jinyuan Ma; Weinan Guo; Chunying Li
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

Review 6.  The role of F-box only protein 31 in cancer.

Authors:  Yuyong Tan; Deliang Liu; Jian Gong; Jia Liu; Jirong Huo
Journal:  Oncol Lett       Date:  2018-01-17       Impact factor: 2.967

7.  F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage.

Authors:  Manas K Santra; Narendra Wajapeyee; Michael R Green
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.